PT-141 10mg Research Peptide Canada

High‑Purity Melanocortin‑Receptor Research Peptide for CNS, Neuroendocrine & Receptor‑Pathway Studies

PT‑141 (Bremelanotide) is a high‑purity, research‑grade melanocortin‑receptor peptide analog widely used in laboratory research involving central nervous system (CNS) signaling, melanocortin‑pathway activation, neuroendocrine regulation, and peptide–receptor interaction dynamics.

Supplied by BlueNexLabs, PT‑141 is provided as a lyophilized peptide (10 mg) with COA‑verified purity, analytical consistency, and audit‑safe Research‑Use‑Only (RUO) labeling, supporting advanced experimental workflows in Canadian research environments.

PT‑141 is a synthetic peptide derived from the α‑MSH (alpha‑melanocyte‑stimulating hormone) sequence, designed to support controlled investigation of melanocortin receptor signaling, particularly within central regulatory pathways.

In research contexts, PT‑141 is frequently referenced in studies examining:

• Melanocortin‑receptor signaling (MC3R / MC4R)
• CNS‑linked neuroendocrine pathways
• Hypothalamic signaling and regulatory networks
• Peptide–receptor binding and activation kinetics
• Structure–function relationships of melanocortin analogs

Its receptor specificity and predictable in‑vitro behavior make PT‑141 a valuable model peptide for CNS‑focused and receptor‑pathway research.

PT‑141 (Bremelanotide) is a synthetic melanocortin‑receptor agonist developed from α‑MSH‑based peptide analogs and used in laboratory research involving central melanocortin signaling systems.

In controlled research environments, PT‑141 is used to study:

• MC3R and MC4R receptor‑pathway activity
• Central melanocortin signaling within the CNS
• Hypothalamic neuroendocrine signaling models
• Peptide–receptor binding affinity and activation profiles
• Neurochemical modulation and central regulatory circuits

Unlike peripherally focused peptides, PT‑141 is primarily referenced for its central receptor‑pathway relevance, supporting CNS‑linked experimental models.

🧬 Melanocortin‑Receptor Activation (MC3R / MC4R)

• Referenced in studies examining melanocortin‑linked transcriptional activity
• Used in CNS‑mediated receptor‑signaling models
• Supports investigation of neuroendocrine‑associated signaling pathways

🧠 Hypothalamic & CNS‑Signaling Pathways

• Applied in research involving central regulatory circuits
• Supports neurochemical‑modulation studies
• Used in multi‑pathway CNS signaling evaluations

🔗 Peptide–Receptor Interaction Dynamics

• Examined in binding‑affinity and activation assays
• Used in comparative analysis versus α‑MSH and related analogs
• Supports peptide‑mediated CNS‑pathway modeling

Type: Synthetic melanocortin‑receptor peptide

Form: Lyophilized powder

Fill Size: 10 mg

Origin: Derived from α‑MSH peptide sequence

Identity Verification: Mass Spectrometry (MS)

Purity Analysis: HPLC / UPLC

Structural & Biochemical Notes

• Demonstrates predictable receptor‑binding behavior in vitro
• Stable in lyophilized form under proper storage conditions
• Sensitive to hydrolysis and oxidation after reconstitution

PT‑141 is commonly referenced in laboratory research involving:

• Melanocortin‑receptor activation and CNS‑signaling models
• Hypothalamic neuroendocrine pathway studies
• Peptide–receptor binding and activation assays
• Neurochemical modulation and central regulatory circuits
• Structure–function analysis of melanocortin‑analog peptides
• Multi‑pathway CNS‑linked transcriptional investigations

Its clean mechanistic profile supports melanocortin-receptor laboratory work. PT-141 is research-use only and is not catalogued for personal use.

• Store lyophilized material at –20 °C, protected from light and moisture
• Reconstituted solutions: 2–8 °C, short-term laboratory use only
• Avoid repeated freeze–thaw cycles; use sterile technique

Batch Certificates of Analysis are listed in the certificates library when published. Match vial size and lot notes before assigning a lot to an assay.

Research-use only. Not for human or veterinary use. No medical, cosmetic, or performance claims are made or implied.